BioMedNewsBreaks

TuesdayMay 20, 2025 9:30 am

BioMedNewsBreaks — VERAXA Biotech AG Appoints Dr. Rick Austin as Chief Scientific Officer

VERAXA Biotech AG, a cancer therapy innovator, and proposed de-SPAC target of Voyager Acquisition Corp. (NASDAQ: VACH), announced the appointment of Rick Austin, Ph.D., as Chief Scientific Officer, effective May 1. Dr. Austin brings more than 25 years of oncology research and development leadership and will help drive VERAXA’s BiTAC(TM) platform and clinical-stage pipeline. He previously served as VP of Research at Harpoon Therapeutics (acquired by Merck in 2024) and held key roles at Amgen and Tularik, contributing to the development of BiTE(R) technologies. Dr. Austin holds a Ph.D. from Yale and has led numerous IND filings, authored over 25…

Continue Reading

TuesdayMay 20, 2025 9:20 am

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Named Exclusive UK and EEA Distributor for ZOLEO Satellite Devices

NextPlat (NASDAQ: NXPL, NXPLW) announced that its subsidiary, Global Telesat Communications Ltd (GTC), has been appointed the exclusive distributor for ZOLEO Inc. across the UK and European Economic Area. ZOLEO's flagship global satellite communicator extends smartphone messaging coverage via the Iridium(R) satellite network and has earned accolades including Outdoor Retailer’s Innovation Award "Product of the Year." The partnership adds to GTC’s expanding e-commerce and Amazon storefront portfolio of satellite connectivity solutions for remote workers, outdoor enthusiasts, and global travelers. To view the full press release, visit: https://ibn.fm/U2bRq About NextPlat Corp NextPlat is a global e-commerce platform company created to capitalize…

Continue Reading

MondayMay 19, 2025 9:41 am

BioMedNewsBreaks — Intelligent Bio Solutions Inc. (Nasdaq: INBS) Expands Remote Workforce Testing with Fingerprint Drug Screening in Australia

Intelligent Bio Solutions (Nasdaq: INBS), a medical technology company focused on rapid, non-invasive testing, successfully completed a full workforce drug screening for Barcaldine Regional Council in Queensland, Australia, using its Intelligent Fingerprinting Drug Screening System. Over 160 employees were tested and cleared within 90 minutes, significantly reducing operational disruption compared to traditional methods. The on-site, fingerprint-based solution enabled same-day results and supported immediate workforce return, highlighting INBS' growing presence in regional and remote testing markets.  To view the full article, visit https://ibn.fm/rJhhJ  About Intelligent Bio Solutions Inc.  Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid,…

Continue Reading

FridayMay 16, 2025 11:27 am

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q1 Loss, Highlights Progress on TPI 287 for Brain Cancer

CNS Pharmaceuticals (NASDAQ: CNSP) reported a Q1 2025 net loss of $4.3 million, up from $3.5 million in the prior year period, as R&D spending increased to support data analysis for its Berubicin trial. The company remains focused on advancing TPI 287, a novel taxane with the potential to treat glioblastoma by crossing the blood-brain barrier. CNS has secured Orphan Drug Designation for TPI 287 and plans to initiate a Phase 2 study in recurrent GBM by late 2025. With $13.1 million in cash at quarter-end and an additional $5 million raised in May, the company expects to fund operations…

Continue Reading

FridayMay 16, 2025 9:00 am

BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Reports Q1 Results, Highlights Progress on Ketamine NDA and HOPE Clinic Rollup 

NRx Pharmaceuticals (NASDAQ: NRXP) reported a Q1 2025 net loss of $5.5 million, down from $6.5 million in the same period last year, with operating losses narrowing to $3.8 million. The company advanced regulatory and commercial milestones for its two lead programs: NRX-100, a preservative-free IV ketamine formulation for suicidal depression now supported by an NDA fee waiver and new patent filing; and NRX-101, an oral treatment for bipolar depression with a PDUFA date anticipated before year-end. Subsidiary HOPE Therapeutics also gained momentum with $10.3 million in new acquisition funding to support a national psychiatry clinic rollup. NRx ended the…

Continue Reading

ThursdayMay 15, 2025 3:35 pm

BioMedNewsBreaks — Adageis’ Fintech Platform Drives Smarter, More Profitable Healthcare

Adageis, a forward-thinking healthcare technology company, is empowering clinics and medical groups to succeed in the shift from fee-for-service to value-based care through its AI-powered platform. The company’s ProActive Care solution deciphers complex insurance contracts, integrates with leading EHR systems, and offers real-time analytics to help providers track revenue trends as well as their performance and profitability. Proprietary components of the platform, including the Value-Based Care Engine and Patented Risk Engine, identify care gaps and high-risk patients, enabling earlier interventions that enhance both clinical and financial performance. By developing targeted solutions, with a focus on smaller and independent practices, Adageis…

Continue Reading

ThursdayMay 15, 2025 2:47 pm

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Strengthens Pharma Footprint Through Key Alliances

Nutriband (NASDAQ: NTRB), a company focused on the development of a portfolio of transdermal pharmaceutical products, is expanding its market presence and manufacturing capabilities through two new strategic partnerships. The company is collaborating with Charlotte FC to build brand visibility, particularly for its AI Tape and AVERSA(TM)—Nutriband’s proprietary technology that it believes has the potential to be the world’s first and only abuse deterrent patch platform for managing chronic pain. The company also deepened its collaboration with Kindeva Drug Delivery through an amended agreement focused on the development of Aversa(TM) Fentanyl, which combines Nutriband’s abuse-deterrent technology with Kindeva’s FDA-approved fentanyl…

Continue Reading

ThursdayMay 15, 2025 2:29 pm

BioMedNewsBreaks — Zacks Research Issues Business Update as Soligenix Inc. (NASDAQ: SNGX) Continues Enrollment in Confirmatory Phase 3 HyBryte Trial 

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company targeting rare diseases, was spotlighted this week in a Zacks Small-Cap Research report that presented a favorable analysis, noting that the company’s Phase 3 cutaneous T-cell lymphoma (“CTCL”) study is continuing and that the trial has a high probability of success.  According to the report, Soligenix is conducting a Phase 3 FLASH2 trial of HyBryte(TM) in patients with CTCL. The Zacks report noted that the FLASH2 trial is similar in design to the recently completed successful Phase 3 FLASH trial. The one key difference between the trials is that in the FLASH trial…

Continue Reading

ThursdayMay 15, 2025 12:38 pm

BioMedNewsBreaks — Intelligent Bio Solutions Inc. (NASDAQ: INBS) Surpasses 450 Accounts as Fingerprint Drug Testing Expands Globally

Intelligent Bio Solutions (NASDAQ: INBS)  reported continued commercial growth, surpassing 450 active accounts with 35 added in fiscal Q3, driven by demand for its rapid, non-invasive fingerprint drug testing system. The company expanded into new sectors including luxury marine, retail, and waste management, while entering remote regions across Europe and Australia. INBS now operates in 24 countries and partners with 18 distributors across 19 nations. These milestones support the company’s global expansion strategy and position it for entry into the multi-billion-dollar U.S. testing market.  To view the full article, visit https://ibn.fm/G4LCD  About Intelligent Bio Solutions Inc.  Intelligent Bio Solutions Inc.…

Continue Reading

ThursdayMay 15, 2025 12:30 pm

BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Subsidiary HOPE Therapeutics Secures $7.8M to Launch Clinic Rollup Strategy

NRx Pharmaceuticals (NASDAQ: NRXP) announced that its wholly owned subsidiary, HOPE Therapeutics(TM), has signed a term sheet with Universal Capital, LLC for $7.8 million in acquisition funding to support the rollout of its national interventional psychiatry clinic network. Combined with previously announced investments, HOPE now has $10.3 million in capital to execute initial acquisitions of Dura Medical, Kadima, and NeuroSpa. These clinics offer neuroplastic treatments such as ketamine and transcranial magnetic stimulation to treat severe depression and PTSD, with current contracts in place to serve veterans through the VA. Universal Capital expects to participate in future funding rounds as HOPE…

Continue Reading